University of Louisville, School of Public Health & Information Sciences, Department of Epidemiology & Population Health, James Graham Brown Cancer Center, Louisville, KY, USA.
University of Louisville, School of Public Health & Information Sciences, Department of Bioinformatics and Biostatistics, Louisville, KY, USA.
Cancer Epidemiol. 2016 Jun;42:108-14. doi: 10.1016/j.canep.2016.04.003. Epub 2016 Apr 18.
Cervical cancer screening, regardless of HPV vaccination, is a cornerstone of cancer prevention. This study evaluated associations between prior HPV vaccine doses and initiation and continued participation of screening by age at vaccination.
Using electronic medical records for a safety net healthcare system (Truman Medical Center), women aged 14-26y vaccinated (n=1123) between 07/01/2006 and 10/1/2009 were randomly selected and matched on birth year and health campus to unvaccinated (n=1123) women. Frequency of screening was determined through 07/01/2013. Hazard ratios (HR) for screening were estimated using Cox proportional hazards regression.
Screening rates were higher after vaccination: unvaccinated (53%), first (62%), second (59%) or third (61%) doses. Women who initiated screening were less likely to complete the vaccine series, regardless of age. Women receiving one dose were more likely than unvaccinated women to initiate screening (HR=2.98 95% Confidence Interval (CI):2.45-3.61) and were more likely to screen than those receiving two (1 vs. 2, HR=2.94 95% CI:2.09-4.14) or three doses (1 vs. 3, HR=3.15 95% CI:2.21-4.48). Compared to unvaccinated women, women <21y who completed 3-doses were 1.8-times more likely to screen at ≥21y, whereas vaccinated women ≥21y were more likely to screen regardless of number of doses (p<0.0001).
Women who were vaccinated were more likely to screen than unvaccinated women; screening rate was highest after and occurred closest to the first vaccine dose. Research evaluating the efficacy of a one-dose vaccine is warranted and may provide both higher vaccination and screening rates.
宫颈癌筛查,无论是否接种 HPV 疫苗,都是癌症预防的基石。本研究评估了 HPV 疫苗接种前接种次数与接种年龄相关的筛查起始和持续参与情况。
利用特鲁曼医疗中心(Truman Medical Center)的电子病历系统,随机选取了 2006 年 7 月 1 日至 2009 年 10 月 1 日期间接种疫苗的 14-26 岁女性(n=1123),并按出生年份和医疗园区与未接种疫苗的女性(n=1123)进行匹配。通过 2013 年 7 月 1 日确定筛查频率。采用 Cox 比例风险回归估计筛查的风险比(HR)。
接种疫苗后筛查率较高:未接种疫苗(53%)、第一针(62%)、第二针(59%)或第三针(61%)。无论年龄大小,开始筛查的女性完成疫苗系列接种的可能性较小。接种一剂疫苗的女性比未接种疫苗的女性更有可能开始筛查(HR=2.98,95%置信区间(CI):2.45-3.61),且比接种两剂(1 比 2,HR=2.94,95% CI:2.09-4.14)或三剂(1 比 3,HR=3.15,95% CI:2.21-4.48)的女性更有可能筛查。与未接种疫苗的女性相比,完成 3 剂疫苗接种的<21 岁女性在≥21 岁时进行筛查的可能性增加 1.8 倍,而≥21 岁的接种疫苗的女性无论接种剂量多少都更有可能进行筛查(p<0.0001)。
与未接种疫苗的女性相比,接种疫苗的女性更有可能进行筛查;接种疫苗后,筛查率最高,且最接近第一剂疫苗接种时间。有必要评估一剂疫苗的疗效研究,这可能会提高疫苗接种和筛查率。